

Special Issue

Cardiomyopathies and Heart Failure: Charting the Future—2nd Edition

Message from the Guest Editor

This Special Issue aims to amass a compilation of articles focusing on cardiomyopathies and their implications in heart failure. We encourage the submission of both original research articles and review papers. Furthermore, given the transformative role of artificial intelligence in medicine, we are particularly interested in studies that explore its application in the realm of cardiomyopathies. Investigations into how artificial intelligence can aid in early detection, treatment optimization, patient monitoring, and novel therapeutic developments are highly encouraged. Topics of interest for this Special Issue include, but are not limited to, the following:

- Various forms of cardiomyopathies and their role in heart failure;
- Early diagnosis and screening methods for cardiomyopathies;
- Risk stratification and patient management in cardiomyopathies;
- Novel therapeutic strategies for treating cardiomyopathies;
- Machine learning algorithms for analyzing cardiac imaging in cardiomyopathies;
- Global health perspectives on cardiomyopathies and heart failure.

We look forward to your contributions.

Guest Editor

Dr. Ali Amr

Institute for Cardiomyopathies Heidelberg (ICH), University Hospital Heidelberg, 69120 Heidelberg, Germany

Deadline for manuscript submissions

30 November 2025



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/238299

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).